A Phase 3 interventional study of MEDI4736 (durvalumab) and Vinorelbine in Non - Small Cell Lung Cancer NSCLC, sponsored by AstraZeneca. Completed at 203 sites in 26 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2024-07-26.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung — 16 open to participants now, 37 under way, 11 of them phase 3. durvalumab · Carcinoma, Non-Small-Cell Lung.
Among the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung, this one is the 11th largest by enrollment, is one of 7 that started in 2015, is one of 17 in phase 3, and was the 10th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →16 of the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 18+
AstraZeneca · Sites in Australia, Georgia, Poland and 2 more countries
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18+
ETOP IBCSG Partners Foundation · Sites in Australia, Austria, Belgium and 7 more countries
Ages 18+
Idris Bahce · Sites in Netherlands
Ages 18+
By country, each count listing its studies:
durvalumab: first FDA approval 2017 (IMFINZI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 130 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, durvalumab is the treatment under test here. Read study by study →
94 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 62 · Phase 3 17 · Phase 4 2
First in 2013; this study’s year is marked. 7 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 597 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 74 across the 94 interventional studies. Of the 47 that completed or were terminated, 27 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 94 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
209 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca: 25 open now, 78 under way, 28 of them phase 3. Of 123 finished, 45 (37%) have results posted.
Among the 209 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca, this one is the 26th largest by enrollment of the 137 interventional ones that give a count, is one of 14 that started in 2015, is one of 44 in phase 3, and was the 70th registered.
AstraZeneca’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
8 of the studies testing durvalumab in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04465968Phase 3National Cancer Center Hospital EastEfficacy and Safety of CRT, Durvalumab and Surgery for SST | 2027-08-31 |
| NCT03965468ETOP IBCSG Partners FoundationImmunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC | 2026-12 |
| NCT04245514Swiss Cancer InstituteMultimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC) | 2026-12-07 |
| NCT06908070Idris BahceChemoradiotherapy With Surgery Followed by Consolidation Durvalumab | 2026-12-17 |
| NCT05206812Yonsei UniversityWindow of Opportunity Trial of Durvalumab (MEDI4736) to Identify Immune Dynamics in Operable Non-small Cell Lung Cancer (NSCLC) (MIRACLE) | 2027-01 |
Add all 8 to your calendar (.ics) → With an account.
Among the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among AstraZeneca’s 209 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
This study is a Phase III, randomised, open label, multi-centre study assessing the efficacy and safety of MEDI4736 (durvalumab) versus Standard of Care in NSCLC patients with PD-L1 positive tumours and the combination of MEDI4736 (durvalumab) plus tremelimumab (MEDI4736+treme) versus Standard of Care in NSCLC patients with PD-L1-negative tumours in the treatment of male and female patients with locally advanced or metastatic NSCLC (Stage IIIB-IV), who have received at least 2 prior systemic treatment regimens including 1 platinum-based chemotherapy regimen for NSCLC. Patients with known EGFR (Epidermal growth factor receptor) tyrosine kinase (TK) activating mutations and anaplastic lymphoma kinase (ALK) rearrangements are not eligible for the study (prospective testing is not planned within this study). The Standard of Care options are: an EGFR tyrosine kinase inhibitor (erlotinib [TARCEVA®]), gemcitabine or vinorelbine (NAVELBINE®)
The study has an umbrella design with 2 sub-studies: sub-study A (randomizing patients with PD-L1 positive tumours 1:1 into MEDI4736 (durvalumab) vs. Standard of Care) and sub-study B (randomizing patients with PD-L1 negative tumours 2:3:1:2 into MEDI4736 (durvalumab) vs. MEDI4736 (durvalumab) plus tremelimumab vs. tremelimumab vs. Standard of Care. The two substudies may have different durations of recruitment periods due to differences in patient population (PD-L1 expression). They may not run concurrently with start and completion of recruitment potentially occurring at different time points.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MEDI4736 (durvalumab) by intravenous infusion. Sub-study A for patients with PD-L1 positive tumors.
Drug: MEDI4736 (durvalumab)
Investigator choice from Vinorelbine, Gemcitabine and Erlotinib. Sub-study A for patients with PD-L1 positive tumors.
Drug: Vinorelbine · Drug: Gemcitabine · Drug: Erlotinib
MEDI4736 (durvalumab) by intravenous infusion and tremelimumab by intravenous infusion. Sub-study B for patients with PD-L1 negative tumors.
Drug: MEDI4736 (durvalumab) in combination with tremelimumab (anti-CTLA4)
Investigator choice from Vinorelbine, Gemcitabine and Erlotinib. Sub-study B for patients with PD-L1 negative tumors.
Drug: Vinorelbine · Drug: Gemcitabine · Drug: Erlotinib
MEDI4736 (durvalumab) by intravenous infusion. Sub-study B for patients with PD-L1 negative tumors.
Drug: MEDI4736 (durvalumab)
tremelimumab by intravenous infusion. Sub-study B for patients with PD-L1 negative tumors.
Drug: tremelimumab (anti-CTLA4)
MEDI4736 (durvalumab) treatment by intravenous infusion
Vinorelbine by intravenous infusion. Administered at a dose of 30 mg/m2 iv on Days 1, 8, 15 and 22 of a 28-day cycle.
Gemcitabine by intravenous infusion. Administered at a dose of 1000 mg/m2 iv over 30 minutes on Days 1, 8, and 15 of a 28-day cycle.
Erlotinib administered at a dose of 150 mg once daily as a tablet for oral administration
Drug page: Durvalumab
MEDI4736 (durvalumab) in combination with tremelimumab (anti-CTLA4) treatment by intravenous infusion
tremelimumab (anti-CTLA4) treatment by intravenous infusion
Overall Survival (OS)
The OS was defined as the time from the date of randomization until death due to any cause.
Time frame: From randomization (Day 1) until death due to any cause, approximately 36 months
Progression-Free Survival (PFS)
The PFS was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdrew from randomized therapy or received another anti-cancer therapy prior to progression. The PFS was determined by Investigator assessments according to response evaluation criteria in solid tumours (RECIST) version 1.1. PD was defined as at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 millimeter (mm) or progression of non-target lesions or the appearance of a new lesion
Time frame: Tumour scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed up to a maximum of approximately 3 years.
OS, Contribution of the Components Analysis of Sub-study B
The OS was defined as the time from the date of randomization until death due to any cause.
Time frame: From randomization (Day 1) until death due to any cause, approximately 36 months
Percentage of Participants Alive at 12 Months (OS12)
The OS12 was defined as the percentage of participants who were alive at 12 months after randomisation per Kaplan-Meier estimate of OS at 12 months.
Time frame: From randomization (Day 1) up to 12 months
PFS, Contribution of the Components Analysis of Sub-study B
The PFS was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdrew from randomized therapy or received another anti-cancer therapy prior to progression. The PFS was determined by Investigator assessments according to RECIST v1.1. PD was defined as at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 millimeter (mm) or progression of non-target lesions or the appearance of a new lesion
Time frame: Tumour scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed up to a maximum of approximately 3 years.
Objective Response Rate (ORR)
The ORR was defined as the percentage of participants with at least 1 visit response of complete response (CR) or partial response (PR) among ITT participants who had measurable disease at baseline. CR was defined as disappearance of all target lesions (any pathological lymph nodes selected as target lesions must have a reduction in short axis to \<10 mm) and PR was defined as at least a 30% decrease in the sum of diameters of target lesions (taking as reference the baseline sum of diameters as long as criteria for PD are not met). The ORR was measured using Investigator assessments according to RECIST v1.1.
Time frame: Tumour scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed up to a maximum of approximately 3 years.
Duration of Response (DoR)
The DoR was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression. The DoR was determined by Investigator assessments according to RECIST v1.1. PD was defined as at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 millimeter (mm) or progression of non-target lesions or the appearance of a new lesion
Time frame: Tumour scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed up to a maximum of approximately 3 years.
Percentage of Participants Alive and Progression Free at 6 Months (APF6)
The APF6 was defined as the percentage of participants who were alive and progression free per RECIST v1.1 at 6 months after randomization per Kaplan-Meier estimate of PFS at 6 months. PD was defined as at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 millimeter (mm) or progression of non-target lesions or the appearance of a new lesion
Time frame: Tumour scans performed at baseline then every ~8 weeks up to 6 months
Percentage of Participants Alive and Progression Free at 12 Months (APF12)
The APF12 was defined as the percentage of participants who were alive and progression free per RECIST v1.1 at 12 months after randomization per Kaplan-Meier estimate of PFS at 12 months. PD was defined as at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 millimeter (mm) or progression of non-target lesions or the appearance of a new lesion
Time frame: Tumour scans performed at baseline then every ~8 weeks up to 12 months.
Time From Randomisation to Second Progression (PFS2) of Sub-study B
The PFS2 was defined as the time from the date of randomization to the earliest of the progression event subsequent to that used for the PFS endpoint or death and determined by local standard clinical practice and have included any of the following: objective radiological, symptomatic progression, or death. PFS2 was reported for sub-study B only.
Time frame: Tumour scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until first progression. Disease then assessed per local practice until 2nd progression. Assessed up to a maximum of approximately 3 years.
This study was divided into 2 parts, sub-study A (82 centers across Europe, Asia, and North America) and sub-study B (149 centers across Europe, Asia, North America, and South America) conducted between 13 January 2015 and 09 February 2018 (data cut-off date).
| Milestone | Sub-study A: Durvalumab | Sub-study A: Standard of Care (SoC) | Sub-study B: Durvalumab+Tremelimumab | Sub-study B: SoC | Sub-study B: Durvalumab | Sub-study B: Tremelimumab |
|---|---|---|---|---|---|---|
| Started | 62 | 64 | 174 | 118 | 117 | 60 |
| Received treatment | 62 | 63 | 173 | 110 | 117 | 60 |
| Completed study treatment | 15 | 0 | 36 | 0 | 23 | 4 |
| Completed | 13 | 5 | 45 | 19 | 29 | 11 |
| Not completed | 49 | 59 | 129 | 99 | 88 | 49 |
| Withdrew: Death | 47 | 48 | 114 | 74 | 77 | 44 |
| Withdrew: Lost to follow-up | 1 | 0 | 2 | 1 | 2 | 1 |
| Withdrew: Withdrawal by subject | 1 | 10 | 11 | 23 | 9 | 4 |
| Withdrew: Eligibility criteria not fulfilled | 0 | 1 | 0 | 1 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 2 | 0 | 0 | 0 |
The OS was defined as the time from the date of randomization until death due to any cause.
| months | Sub-study A: Durvalumab | Sub-study A: SoC | Sub-study B: Durvalumab+Tremelimumab | Sub-study B: SoC |
|---|---|---|---|---|
| Overall Survival (OS) | 11.7 (8.2 to 17.4) | 6.8 (4.9 to 10.2) | 11.5 (8.7 to 14.1) | 8.7 (6.5 to 11.7) |
The PFS was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdrew from randomized therapy or received another anti-cancer therapy prior to progression. The PFS was determined by Investigator assessments according to response evaluation criteria in solid tumours (RECIST) version 1.1. PD was defined as at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 millimeter (mm) or progression of non-target lesions or the appearance of a new lesion
| months | Sub-study A: Durvalumab | Sub-study A: SoC | Sub-study B: Durvalumab+Tremelimumab | Sub-study B: SoC |
|---|---|---|---|---|
| Progression-Free Survival (PFS) | 3.8 (1.9 to 5.6) | 2.2 (1.9 to 3.7) | 3.5 (2.3 to 4.6) | 3.5 (1.9 to 3.9) |
The OS was defined as the time from the date of randomization until death due to any cause.
| months | Sub-study B: Durvalumab+Tremelimumab | Sub-study B: Durvalumab | Sub-study B: Tremelimumab |
|---|---|---|---|
| OS, Contribution of the Components Analysis of Sub-study B | 11.5 (8.7 to 14.1) | 10.0 (7.1 to 13.2) | 6.9 (3.9 to 13.2) |
The OS12 was defined as the percentage of participants who were alive at 12 months after randomisation per Kaplan-Meier estimate of OS at 12 months.
| percentage of participants | Sub-study A: Durvalumab | Sub-study A: SoC | Sub-study B: Durvalumab+Tremelimumab | Sub-study B: SoC | Sub-study B: Durvalumab | Sub-study B: Tremelimumab |
|---|---|---|---|---|---|---|
| Percentage of Participants Alive at 12 Months (OS12) | 49.3 (36.3 to 61.0) | 31.3 (20.2 to 43.0) | 49.5 (41.7 to 56.7) | 38.8 (29.9 to 47.7) | 43.6 (34.4 to 52.4) | 41.2 (28.7 to 53.3) |
The PFS was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdrew from randomized therapy or received another anti-cancer therapy prior to progression. The PFS was determined by Investigator assessments according to RECIST v1.1. PD was defined as at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 millimeter (mm) or progression of non-target lesions or the appearance of a new lesion
| months | Sub-study B: Durvalumab+Tremelimumab | Sub-study B: Durvalumab | Sub-study B: Tremelimumab |
|---|---|---|---|
| PFS, Contribution of the Components Analysis of Sub-study B | 3.5 (2.3 to 4.6) | 3.1 (1.9 to 3.7) | 2.1 (1.8 to 3.2) |
The ORR was defined as the percentage of participants with at least 1 visit response of complete response (CR) or partial response (PR) among ITT participants who had measurable disease at baseline. CR was defined as disappearance of all target lesions (any pathological lymph nodes selected as target lesions must have a reduction in short axis to \<10 mm) and PR was defined as at least a 30% decrease in the sum of diameters of target lesions (taking as reference the baseline sum of diameters as long as criteria for PD are not met). The ORR was measured using Investigator assessments according to RECIST v1.1.
| percentage of participants | Sub-study A: Durvalumab | Sub-study A: SoC | Sub-study B: Durvalumab+Tremelimumab | Sub-study B: SoC | Sub-study B: Durvalumab | Sub-study B: Tremelimumab |
|---|---|---|---|---|---|---|
| Objective Response Rate (ORR) | 35.5 | 12.5 | 14.9 | 6.8 | 15.4 | 6.7 |
The DoR was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression. The DoR was determined by Investigator assessments according to RECIST v1.1. PD was defined as at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 millimeter (mm) or progression of non-target lesions or the appearance of a new lesion
| months | Sub-study A: Durvalumab | Sub-study A: SoC | Sub-study B: Durvalumab+Tremelimumab | Sub-study B: SoC | Sub-study B: Durvalumab | Sub-study B: Tremelimumab |
|---|---|---|---|---|---|---|
| Duration of Response (DoR) | 9.5 (3.0 to 17.8) | 4.8 (1.9 to 7.6) | 12.2 (6.5 to NA) | 10.8 (5.6 to 12.2) | 10.0 (4.0 to NA) | 4.7 (2.9 to NA) |
The APF6 was defined as the percentage of participants who were alive and progression free per RECIST v1.1 at 6 months after randomization per Kaplan-Meier estimate of PFS at 6 months. PD was defined as at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 millimeter (mm) or progression of non-target lesions or the appearance of a new lesion
| percentage of participants | Sub-study A: Durvalumab | Sub-study A: SoC | Sub-study B: Durvalumab+Tremelimumab | Sub-study B: SoC | Sub-study B: Durvalumab | Sub-study B: Tremelimumab |
|---|---|---|---|---|---|---|
| Percentage of Participants Alive and Progression Free at 6 Months (APF6) | 35.5 (23.9 to 47.3) | 24.1 (14.1 to 35.6) | 31.5 (24.6 to 38.7) | 27.6 (19.0 to 36.7) | 27.2 (19.4 to 35.6) | 14.5 (6.9 to 24.9) |
The APF12 was defined as the percentage of participants who were alive and progression free per RECIST v1.1 at 12 months after randomization per Kaplan-Meier estimate of PFS at 12 months. PD was defined as at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 millimeter (mm) or progression of non-target lesions or the appearance of a new lesion
| percentage of participants | Sub-study A: Durvalumab | Sub-study A: SoC | Sub-study B: Durvalumab+Tremelimumab | Sub-study B: SoC | Sub-study B: Durvalumab | Sub-study B: Tremelimumab |
|---|---|---|---|---|---|---|
| Percentage of Participants Alive and Progression Free at 12 Months (APF12) | 19.4 (10.7 to 30.0) | 9.9 (3.8 to 19.3) | 20.6 (14.7 to 27.1) | 8.0 (3.4 to 15.2) | 15.0 (9.1 to 22.3) | 7.3 (2.4 to 16.0) |
The PFS2 was defined as the time from the date of randomization to the earliest of the progression event subsequent to that used for the PFS endpoint or death and determined by local standard clinical practice and have included any of the following: objective radiological, symptomatic progression, or death. PFS2 was reported for sub-study B only.
| months | Sub-study B: Durvalumab+Tremelimumab | Sub-study B: SoC | Sub-study B: Durvalumab | Sub-study B: Tremelimumab |
|---|---|---|---|---|
| Time From Randomisation to Second Progression (PFS2) of Sub-study B | 9.1 (6.6 to 12.3) | 6.7 (4.7 to 8.9) | 8.0 (6.3 to 10.0) | 5.7 (3.2 to 10.0) |
Collected over From signature of informed consent up to 90 days after the last dose of durvalumab and/or tremelimumab and 30 days after the last dose of SoC, approximately 15 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sub-study A: Durvalumab | 48/62 (77.4%) | 23/62 (37.1%) | 52/62 (83.9%) |
| Sub-study A: SoC | 55/64 (85.9%) | 16/63 (25.4%) | 59/63 (93.7%) |
| Sub-study B: Durvalumab+Tremelimumab | 118/174 (67.8%) | 65/173 (37.6%) | 139/173 (80.3%) |
| Sub-study B: SoC | 90/118 (76.3%) | 28/110 (25.5%) | 100/110 (90.9%) |
| Sub-study B: Durvalumab | 83/117 (70.9%) | 36/117 (30.8%) | 99/117 (84.6%) |
| Sub-study B: Tremelimumab | 46/60 (76.7%) | 23/60 (38.3%) | 48/60 (80%) |
| Event | Sub-study A: Durvalumab | Sub-study A: SoC | Sub-study B: Durvalumab+Tremelimumab | Sub-study B: SoC | Sub-study B: Durvalumab | Sub-study B: Tremelimumab |
|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 0/62 | 0/63 | 3/173 | 0/110 | 1/117 | 7/60 |
| ColitisGastrointestinal disorders | 1/62 | 0/63 | 3/173 | 0/110 | 0/117 | 5/60 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/62 | 5/63 | 0/173 | 0/110 | 0/117 | 0/60 |
| PneumoniaInfections and infestations | 4/62 | 3/63 | 7/173 | 2/110 | 2/117 | 2/60 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 3/62 | 0/63 | 2/173 | 0/110 | 1/117 | 2/60 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/62 | 0/63 | 7/173 | 2/110 | 2/117 | 0/60 |
| Clostridium difficile colitisInfections and infestations | 0/62 | 0/63 | 0/173 | 0/110 | 0/117 | 2/60 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 1/62 | 0/63 | 1/173 | 1/110 | 1/117 | 2/60 |
| SepsisInfections and infestations | 2/62 | 0/63 | 0/173 | 0/110 | 1/117 | 0/60 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 2/62 | 0/63 | 5/173 | 1/110 | 1/117 | 1/60 |
| Event | Sub-study A: Durvalumab | Sub-study A: SoC | Sub-study B: Durvalumab+Tremelimumab | Sub-study B: SoC | Sub-study B: Durvalumab | Sub-study B: Tremelimumab |
|---|---|---|---|---|---|---|
| Decreased appetiteMetabolism and nutrition disorders | 16/62 | 20/63 | 34/173 | 23/110 | 27/117 | 12/60 |
| AnaemiaBlood and lymphatic system disorders | 5/62 | 17/63 | 17/173 | 27/110 | 11/117 | 5/60 |
| DiarrhoeaGastrointestinal disorders | 9/62 | 8/63 | 36/173 | 18/110 | 25/117 | 16/60 |
| ConstipationGastrointestinal disorders | 13/62 | 15/63 | 14/173 | 11/110 | 15/117 | 4/60 |
| NauseaGastrointestinal disorders | 11/62 | 15/63 | 28/173 | 22/110 | 20/117 | 11/60 |
| PruritusSkin and subcutaneous tissue disorders | 7/62 | 2/63 | 28/173 | 5/110 | 11/117 | 14/60 |
| FatigueGeneral disorders | 10/62 | 10/63 | 25/173 | 24/110 | 22/117 | 4/60 |
| PyrexiaGeneral disorders | 9/62 | 6/63 | 20/173 | 23/110 | 12/117 | 6/60 |
| AstheniaGeneral disorders | 6/62 | 8/63 | 31/173 | 17/110 | 16/117 | 9/60 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 11/62 | 9/63 | 25/173 | 15/110 | 16/117 | 6/60 |
Sub-study A and B: Full analysis set (FAS) included all randomized participants analyzed on an intent-to-treat (ITT) basis.
| Age, Customized(Participants) | Sub-study A: Durvalumab | Sub-study A: SoC | Sub-study B: Durvalumab+Tremelimumab | Sub-study B: SoC | Sub-study B: Durvalumab | Sub-study B: Tremelimumab | Total |
|---|---|---|---|---|---|---|---|
| <50 years | 3 | 11 | 16 | 8 | 13 | 4 | 55 |
| >=50 to <65 years | 31 | 25 | 79 | 49 | 52 | 27 | 263 |
| >=65 to <75 years | 24 | 21 | 64 | 50 | 39 | 24 | 222 |
| >=75 years | 4 | 7 | 15 | 11 | 13 | 5 | 55 |
| Sex: Female, Male(Participants) | Sub-study A: Durvalumab | Sub-study A: SoC | Sub-study B: Durvalumab+Tremelimumab | Sub-study B: SoC | Sub-study B: Durvalumab | Sub-study B: Tremelimumab | Total |
|---|---|---|---|---|---|---|---|
| Female | 20 | 16 | 59 | 37 | 44 | 21 | 197 |
| Male | 42 | 48 | 115 | 81 | 73 | 39 | 398 |
| Race/Ethnicity, Customized(Participants) | Sub-study A: Durvalumab | Sub-study A: SoC | Sub-study B: Durvalumab+Tremelimumab | Sub-study B: SoC | Sub-study B: Durvalumab | Sub-study B: Tremelimumab | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 22 | 23 | 41 | 41 | 34 | 16 | 177 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 3 | 2 | 2 | 1 | 9 |
| White | 40 | 40 | 129 | 74 | 79 | 43 | 405 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Other | 0 | 0 | 1 | 1 | 1 | 0 | 3 |
Showing the first 100 of 203 sites across 26 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Jan 2015 to primary completion in Feb 2018, 36 months.
Results were first posted in Apr 2019, 1 year 2 months after primary completion.
Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 36 months is close to that.
Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Durvalumab · Tremelimumab
Carcinoma, Non-Small-Cell Lung →